睾酮替代疗法市场机会、成长动力、行业趋势分析和 2025 - 2034 年预测

2024 年全球睪固酮替代疗法市场规模达到 19 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 4.2%。随着越来越多的男性寻求解决睪固酮缺乏症的方法，治疗方法的进步和荷尔蒙替代疗法的日益接受正在推动需求。

宣传活动的增加、医疗保健基础设施的改善以及以患者为中心的药物输送系统使得睾酮替代疗法更加容易获得。个人化医疗的转变和治疗配方的创新进一步加速了市场发展势头。这些发展确保了睪固酮替代疗法市场仍是满足荷尔蒙缺乏症患者需求的重点。

2024 年，注射剂占据市场主导地位，创造 11 亿美元的收入。这些产品由于能够提供稳定且可预测的睪固酮水平而优于凝胶和贴片。由于注射剂具有可靠的生物利用度、易于调整剂量以及客製化治疗计划的能力，已成为患者和医疗保健提供者的首选。这些好处有助于改善患者的治疗效果，确保注射剂在睪固酮替代疗法市场的领导地位。

在活性成分中，环戊丙酸睪酮占据领先地位，2024 年的收入为 6.361 亿美元，预计到 2034 年的复合年增长率为 4.5%。这种便利性提高了患者的依从性，并使该化合物成为寻求有效且易于管理的治疗方案的医疗保健提供者的首选。

2024 年美国睪固酮替代疗法市场收入将达到 7.361 亿美元，预测期内预计复合年增长率为 3.5%。完善的医疗保健基础设施、领先製药商的存在以及优惠的报销政策支持了市场的成长。凝胶、贴片和注射等给药方式的创新提高了药物的可及性和患者的接受度。对这些先进疗法的需求不断增长，凸显了该国在全球睾酮替代疗法市场的主导地位。

目录

第 1 章：方法论与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 性腺功能低下盛行率不断上升
    • 药物传输的进展
    • 对性腺功能低下的认识不断提高
    • 老龄人口不断扩大
  • 产业陷阱与挑战
    • 副作用和风险
• 成长潜力分析
• 2024 年定价分析
• 监管格局
• 报销场景
• 技术格局
• 管道分析
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第 5 章：市场估计与预测：按产品类型，2021 年至 2034 年

• 主要趋势
• 注射剂
• 专题
• 其他产品类型

第 6 章：市场估计与预测：按活性成分，2021 年至 2034 年

• 主要趋势
• 环戊丙酸睪酮
• 睪固酮
• 庚酸睪酮
• 十一酸睪酮
• 其他活性成分

第 7 章：市场估计与预测：按配销通路，2021 年至 2034 年

• 主要趋势
• 传统实体店
• 电子商务

第 8 章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• AbbVie
• Antares Pharma
• Cipla
• Eli Lilly & Co.
• Endo International
• Ferring Pharmaceuticals
• Halozyme
• Lupin
• Marius Pharmaceuticals
• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceuticals
• Tolmar

The Global Testosterone Replacement Therapy Market reached USD 1.9 billion in 2024 and is set to expand at a CAGR of 4.2% between 2025 and 2034. This growth is fueled by the rising incidences of hypogonadism and increased awareness about its diagnosis and treatment options. As more men seek solutions for testosterone deficiency, advancements in therapeutic approaches and growing acceptance of hormone replacement therapies are driving demand.

A surge in awareness campaigns, improved healthcare infrastructure, and patient-focused drug delivery systems have made testosterone replacement therapy more accessible. The shift toward personalized medicine and innovations in treatment formulations are further accelerating market momentum. These developments ensure that the testosterone replacement therapy market remains a key focus in addressing the needs of patients suffering from hormonal deficiencies.

In 2024, injectables dominated the market, generating USD 1.1 billion in revenue. These products outperform gels and patches due to their ability to provide stable and predictable testosterone levels. With reliable bioavailability, ease of dosage adjustment, and the capability to tailor treatment plans, injectables have become the preferred choice for both patients and healthcare providers. These benefits contribute to better patient outcomes, securing injectables' leadership position in the testosterone replacement therapy market.

Among active ingredients, testosterone cypionate led the segment, accounting for USD 636.1 million in revenue in 2024, and anticipated to grow at a CAGR of 4.5% through 2034. Known for its extended duration of action, testosterone cypionate typically requires injections only once every one to two weeks, significantly reducing the frequency of administration. This convenience improves patient adherence and has established the compound as a go-to option for healthcare providers seeking effective and manageable treatment solutions.

The U.S. testosterone replacement therapy market reached USD 736.1 million in revenue in 2024, with a projected CAGR of 3.5% over the forecast period. The market's growth is supported by a well-established healthcare infrastructure, the presence of leading pharmaceutical manufacturers, and favorable reimbursement policies. Innovations in delivery methods, such as gels, patches, and injections, have increased accessibility and patient acceptance. Rising demand for these advanced therapies underscores the country's dominant position in the global testosterone replacement therapy market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hypogonadism
    • 3.2.1.2 Advancements in drug delivery
    • 3.2.1.3 Growing awareness about hypogonadism
    • 3.2.1.4 Expanding aging population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and risks
• 3.3 Growth potential analysis
• 3.4 Pricing analysis, 2024
• 3.5 Regulatory landscape
• 3.6 Reimbursement scenario
• 3.7 Technology landscape
• 3.8 Pipeline analysis
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Injectables
• 5.3 Topicals
• 5.4 Other product types

Chapter 6 Market Estimates and Forecast, By Active Ingredients, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Testosterone cypionate
• 6.3 Testosterone
• 6.4 Testosterone enanthate
• 6.5 Testosterone undecanoate
• 6.6 Other active ingredients

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Brick & mortar
• 7.3 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Antares Pharma
• 9.3 Cipla
• 9.4 Eli Lilly & Co.
• 9.5 Endo International
• 9.6 Ferring Pharmaceuticals
• 9.7 Halozyme
• 9.8 Lupin
• 9.9 Marius Pharmaceuticals
• 9.10 Pfizer
• 9.11 Sun Pharmaceutical Industries
• 9.12 Teva Pharmaceuticals
• 9.13 Tolmar